2,465 Stryker Corporation $SYK Shares Sold by Childress Capital Advisors LLC

Childress Capital Advisors LLC cut its stake in Stryker Corporation (NYSE:SYK) by 72.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 934 shares of the medical technology company’s stock after selling 2,465 shares during the quarter. Childress Capital Advisors LLC’s holdings in Stryker were worth $257,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. D.A. Davidson & CO. raised its stake in Stryker by 3.3% in the third quarter. D.A. Davidson & CO. now owns 95,169 shares of the medical technology company’s stock valued at $26,209,000 after buying an additional 2,997 shares during the last quarter. LaFleur & Godfrey LLC boosted its holdings in Stryker by 9.4% in the third quarter. LaFleur & Godfrey LLC now owns 82,899 shares of the medical technology company’s stock worth $22,830,000 after acquiring an additional 7,133 shares in the last quarter. North Dakota State Investment Board grew its stake in shares of Stryker by 3.5% during the third quarter. North Dakota State Investment Board now owns 10,592 shares of the medical technology company’s stock worth $2,917,000 after acquiring an additional 357 shares during the last quarter. Laurel Wealth Advisors LLC purchased a new stake in shares of Stryker during the third quarter worth about $42,000. Finally, BLB&B Advisors LLC grew its stake in shares of Stryker by 3.4% during the third quarter. BLB&B Advisors LLC now owns 39,060 shares of the medical technology company’s stock worth $10,757,000 after acquiring an additional 1,273 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SYK shares. Raymond James Financial restated an “outperform” rating and set a $323.00 price objective on shares of Stryker in a report on Friday. Royal Bank Of Canada lowered their target price on shares of Stryker from $420.00 to $375.00 and set an “outperform” rating for the company in a research note on Friday. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. TD Cowen cut their price target on shares of Stryker from $298.00 to $290.00 and set a “hold” rating on the stock in a research note on Friday. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Sixteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $355.84.

Stryker Price Performance

NYSE:SYK opened at $291.56 on Friday. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $111.83 billion, a PE ratio of 31.05, a price-to-earnings-growth ratio of 1.88 and a beta of 0.78. The stock’s 50-day moving average price is $292.83 and its 200-day moving average price is $324.51.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a net margin of 13.78% and a return on equity of 23.83%. The firm had revenue of $6.52 billion during the quarter, compared to analysts’ expectations of $6.62 billion. During the same quarter in the previous year, the business posted $3.19 EPS. The company’s revenue for the quarter was up 7.6% on a year-over-year basis. As a group, equities analysts expect that Stryker Corporation will post 14.85 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Insider Activity

In related news, Director Ronda Stryker sold 300,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This trade represents a 11.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last quarter. Insiders own 4.60% of the company’s stock.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.